Dual Antiplatelet Therapy Improves Functional Outcome in Patients With Progressive Lacunar Strokes

Hypertension, diabetes mellitus, or hypercholesterolemia was defined as diagnosis made before admission or systolic blood pressure ≥140 mm Hg, HbA1c ≥6.5, or LDL-cholesterol ≥120 mg/dL. For lacunar syndromes, only symptoms regarding paresis and sensory symptoms were revised. Most patients had additional facial paresis or dysarthria. END indicates early neurological deterioration; HbA1c, hemoglobin A1c; IQR, interquartile range; LDL, low-density lipoprotein; and TIA, transient ischemic attack.

For efficacy end points, NIHSS and Rankin Scale scores were compared between discharge and admission. P values of DAPT efficacy were calculated with Fisher exact test. DAPT indicates dual anti-platelet therapy; and NIHSS, National Institutes of Health Stroke Scale.

Authors and Disclosures

Anne Berberich, MD, Christine Schneider, MD, Tilman Reiff, MD, Christoph Gumbinger, MD and Peter Arthur Ringleb, MD

Department of Neurology, Heidelberg University Hospital, Germany.

Correspondence to
Anne Berberich, MD, Department of Neurology, Heidelberg University Hospital, Im Neuenheimer Feld 400, D-69120 Heidelberg, Germany. Email anne.berberich@med.uni-heidelberg.de

Disclosures
None.